Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell� Model With a Focus on Oncology
Tevogen.AI (NASDAQ:TVGNW) announced an expanded collaboration with Microsoft and Databricks to develop the beta version of its PredicTcell� model, focusing on oncology applications. The company will enhance its AI model by combining oncology datasets with existing virology data to improve prediction accuracy for immunologically active peptides.
The initiative builds upon Tevogen.AI's recently published international patent application (WO 2025/129197) for novel machine learning systems. The enhanced PredicTcell model aims to accelerate cancer immunotherapy development and will include advanced analytics and visualization tools to support internal R&D teams.
Tevogen.AI (NASDAQ:TVGNW) ha annunciato un ampliamento della collaborazione con Microsoft e Databricks per sviluppare la versione beta del suo modello PredicTcell�, con un focus sulle applicazioni in oncologia. L'azienda potenzierà il suo modello di intelligenza artificiale combinando dataset oncologici con dati virologici esistenti per migliorare la precisione nella previsione dei peptidi immunologicamente attivi.
L'iniziativa si basa sulla recente domanda di brevetto internazionale di Tevogen.AI (WO 2025/129197) relativa a nuovi sistemi di machine learning. Il modello PredicTcell potenziato mira ad accelerare lo sviluppo dell'immunoterapia oncologica e includerà strumenti avanzati di analisi e visualizzazione per supportare i team di ricerca e sviluppo interni.
Tevogen.AI (NASDAQ:TVGNW) anunció una colaboración ampliada con Microsoft y Databricks para desarrollar la versión beta de su modelo PredicTcellâ„�, centrado en aplicaciones oncológicas. La compañÃa mejorará su modelo de IA combinando conjuntos de datos oncológicos con datos virológicos existentes para aumentar la precisión en la predicción de péptidos inmunológicamente activos.
La iniciativa se basa en la solicitud de patente internacional recientemente publicada por Tevogen.AI (WO 2025/129197) para sistemas novedosos de aprendizaje automático. El modelo PredicTcell mejorado tiene como objetivo acelerar el desarrollo de inmunoterapias contra el cáncer e incluirá herramientas avanzadas de análisis y visualización para apoyar a los equipos internos de I+D.
Tevogen.AI (NASDAQ:TVGNW)µç� Microsoft ë°� Databricks와ì� í˜‘ë ¥ì� 확대하여 ì•� 치료 ì‘ìš©ì—� 중ì ì� ë‘� PredicTcellâ„� 모ë¸ì� ë² íƒ€ ë²„ì „ì� 개발한다ê³� 발표했습니다. 회사µç� 기존ì� ë°”ì´ëŸ¬ìФí•� ë°ì´í„°ì™€ ì•� ê´€ë � ë°ì´í„°ì…‹ì� 결합하여 ë©´ì—í•™ì 으로 í™œì„±í™”ëœ íŽ©íƒ€ì´ë“œ 예측 ì •í™•ë„를 í–¥ìƒì‹œí‚¬ ì˜ˆì •ìž…ë‹ˆë‹�.
ì� ì´ë‹ˆì…”티브µç” Tevogen.AIê°€ 최근 공개í•� êµì œ 특허 ì¶œì›ì„�(WO 2025/129197)ì—서 ì œì•ˆí•� 새로ìš� ë¨¸ì‹ ëŸ¬ë‹ ì‹œìŠ¤í…œì„ ê¸°ë°˜ìœ¼ë¡œ 합니ë‹�. í–¥ìƒë� PredicTcell 모ë¸ì€ ì•� ë©´ì—치료 개발ì� ê°€ì†í™”하µç” ê²ƒì„ ëª©í‘œë¡� 하며, ë‚´ë¶€ 연구개발 팀ì� ì§€ì›í•˜ê¸� 위한 ê³ ê¸‰ ë¶„ì„ ë°� 시ê°í™� ë„구ë¥� í¬í•¨í•� 것입니다.
Tevogen.AI (NASDAQ:TVGNW) a annoncé une collaboration renforcée avec Microsoft et Databricks pour développer la version bêta de son modèle PredicTcell�, axé sur les applications en oncologie. L'entreprise améliorera son modèle d'IA en combinant des ensembles de données oncologiques avec des données virologiques existantes afin d'améliorer la précision de la prédiction des peptides immunologiquement actifs.
Cette initiative s'appuie sur la récente demande de brevet international publiée par Tevogen.AI (WO 2025/129197) concernant de nouveaux systèmes d'apprentissage automatique. Le modèle PredicTcell amélioré vise à accélérer le développement de l'immunothérapie contre le cancer et inclura des outils avancés d'analyse et de visualisation pour soutenir les équipes internes de R&D.
Tevogen.AI (NASDAQ:TVGNW) gab eine erweiterte Zusammenarbeit mit Microsoft und Databricks bekannt, um die Beta-Version seines PredicTcell�-Modells zu entwickeln, das sich auf onkologische Anwendungen konzentriert. Das Unternehmen wird sein KI-Modell verbessern, indem es onkologische Datensätze mit bestehenden Virologiedaten kombiniert, um die Vorhersagegenauigkeit für immunologisch aktive Peptide zu erhöhen.
Die Initiative baut auf der kürzlich veröffentlichten internationalen Patentanmeldung von Tevogen.AI (WO 2025/129197) für neuartige Machine-Learning-Systeme auf. Das verbesserte PredicTcell-Modell soll die Entwicklung von Krebsimmuntherapien beschleunigen und wird fortschrittliche Analyse- und Visualisierungstools enthalten, um interne F&E-Teams zu unterstützen.
- Recent international patent application (WO 2025/129197) for novel machine learning systems
- Expansion of PredicTcell model to include oncology applications, broadening market potential
- Strategic partnerships with major tech companies Microsoft and Databricks
- Potential new revenue stream through external market opportunities
- Limited operating history in AI development
- Need for additional capital to execute business plan
- Significant competition in AI drug discovery space
- Regulatory uncertainties in AI-driven drug development
Insights
Tevogen.AI expands Microsoft/Databricks partnership to build oncology-focused PredicTcell beta, potentially creating new revenue streams and accelerating cancer immunotherapy development.
Tevogen.AI is making strategic advances in the competitive AI-driven drug discovery landscape through its expanded collaboration with tech giants Microsoft and Databricks. The company is now building a beta version of its PredicTcell model with a newly curated oncology dataset that will complement its existing virology data. This expansion is particularly significant as it follows Tevogen's recently published international patent application (WO 2025/129197) for novel machine learning systems that predict immunologically active peptides.
The technical progression from alpha to beta version represents a crucial development milestone. By focusing on oncology—one of the most challenging areas in drug discovery due to disease complexity and limited high-quality datasets—Tevogen is targeting a high-value therapeutic segment. This strategic focus could potentially accelerate cancer immunotherapy development while simultaneously creating new revenue opportunities through external market applications.
The development of enhanced analytics and visualization tools for the PredicTcell model suggests Tevogen is building a comprehensive platform rather than a single-use technology. This approach could create multiple commercialization pathways: supporting internal R&D efficiency, licensing opportunities to other pharmaceutical companies, and potentially offering AI-as-a-service solutions in the precision medicine space.
While the press release indicates promising technological advancement, investors should note the early stage of this AI initiative. The beta version development signals progress but still precedes full commercial deployment. The collaboration with established tech leaders provides technical validation and access to advanced cloud computing resources, potentially reducing development risks and accelerating time-to-market for Tevogen's AI-driven drug discovery platform.
- Tevogen.AI to explore external market opportunities as a potential revenue source.
- Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development.
- Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams.
WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.� or “Company�) (Nasdaq: ) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: ) and Databricks, to build the beta version of its foundational PredicTcell model.
Powered by the Databricks Data Intelligence Platform and backed by their innovative engineering teams, Tevogen.AI has begun curating a dataset focused on oncology. The dataset, aggregated with the initial virology dataset. aims to improve upon the accuracy of the alpha version of PredicTcell model.
This next phase of development builds on Tevogen.AI’s recently published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases.
“We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,� said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. “Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.�
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,� “could,� “would,� “expect,� “anticipate,� “possible,� “potential,� “goal,� “opportunity,� “project,� “believe,� “future,� and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
